Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system. The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had […]
Abbott CEO on Libre: ‘We’re just getting started’
Abbott (NYSE:ABT) posted its third quarter financial results yesterday, meeting its own forecast and the consensus set by analysts on Wall Street. The healthcare giant also narrowed its earnings outlook for the rest of the year. Abbott noted particularly high gains in revenue for its medical device division – sales were up 8.4% to $2.82 billion, in […]
Abbott’s next-gen FreeStyle Libre wins CE Mark
Abbott (NYSE:ABT) said today that its next-generation FreeStyle Libre system won CE Mark clearance in the European Union. The glucose monitor, which eliminates the need for finger sticks, features optional alarms that users can customize, according to Abbott. “The FreeStyle Libre 2 system is designed to further empower people with diabetes by providing a choice about […]
TCT 2018: Boston Scientific wins FDA nod for drug-eluting vascular stent
On the heels of positive study results at the 30th Transcatheter Cardiovascular Therapeutics meeting, Boston Scientific (NYSE:BSX) won FDA approval for its drug-eluting vascular stent system, Eluvia. The device, which is designed for the treatment of peripheral artery disease, uses a drug-polymer combination to deliver paclitaxel over the course of a year. “Over the past decade, we’ve […]
Livongo adds compatibility with Abbott’s FreeStyle Libre Pro
Livongo Health said today it will integrate continuous glucose data from Abbott‘s (NYSE:ABT) FreeStyle Libre Pro system into its Livongo for Diabetes system, touting it as the first such system to integrate data from Abbott’s FreeStyle Libre Pro. With the integration, users of the FreeStyle Libre Pro will be able to see a visual snapshot of […]
MicroPort’s drug-eluting stent performs well in European study
MicroPort Scientific’s Firehawk rapamycin target eluting coronary stent performed comparably to Abbott’s Xience stent family in a study just published in The Lancet. The TARGET AC multi-center, randomized controlled trial enrolled 1,653 patients at 21 clinical study sites in Europe. Firehawk met the trial’s non-inferiority primary endpoint of target lesion failure rate at 12 months of 6.1% versus […]
Abbott wins FDA nod for 14-day FreeStyle Libre glucose sensor
Abbott (NYSE:ABT) said today that the FDA approved its 14-day FreeStyle Libre flash glucose monitor, making the device the longest lasting self-applied glucose sensor on the market. The company’s FreeStyle Libre system, initially approved to last 10 days, is designed to eliminate the need for fingersticks. Users can test their blood sugar with the continuous glucose […]
Abbott CEO aims for more than one million Libre users by 2019
Topping estimates on Wall Street, Abbott (NYSE:ABT) posted a hefty beat yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre. “Libre offers a true mass-market opportunity with its […]
Sales for Abbott’s diabetes business jump 40% in Q2
Abbott (NYSE:ABT) shares were up today after the healthcare company posted second-quarter financial results that topped estimates on Wall Street. For the three months ended June 30, Abbott posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion. The company saw its quarterly profits grow 159% on sales growth of 17% compared […]
FDA approves Abbott’s latest drug-eluting stent
Abbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent. The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott. “We […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn